OncoMatch/Clinical Trials/NCT06856187
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
Is NCT06856187 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including TAS-102+bevacizumab+local treatment and Standard chemotherapy for metastatic colorectal cancer (crc).
Treatment: TAS-102+bevacizumab+local treatment · Standard chemotherapy — This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local treatment versus continuous treatment of standard second-line therapy in advanced colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: first-line standard therapy
Patients who have failed first-line standard therapy and are intended to receive second-line standard therapy
Cannot have received: TAS-102 (TAS-102)
Prior treatment with TAS-102
Lab requirements
Blood counts
Adequate major organ function
Kidney function
Adequate major organ function
Liver function
Adequate major organ function
Adequate major organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify